Novavax CEO Rahul Singhvi - An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Vaccine firm tells "The Pink Sheet" DAILY about its virus-like particles process for making vaccines and how its processes can be less expensive and require smaller facilities.
You may also be interested in...
PIPE Proceeds In Hand, Novavax Looks To Score With Two Late-Stage Flu Vaccines
Vaccine-focused biotech says it has sufficient cash to continue business strategy through third-quarter 2009.
PIPE Proceeds In Hand, Novavax Looks To Score With Two Late-Stage Flu Vaccines
Vaccine-focused biotech says it has sufficient cash to continue business strategy through third-quarter 2009.
Dose-Ranging Trial Of Novavax Pandemic Flu Vaccine Demonstrates Immunogenicity
Firm says further development of vaccine for Indonesia 2005 strain requires either co-development partner or government contracts.